Publication: Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
dc.contributor.coauthor | Efe, Cumalı | |
dc.contributor.coauthor | Lammert, Craig | |
dc.contributor.coauthor | Taşçılar, Koray | |
dc.contributor.coauthor | Dhanasekaran, Renumathy | |
dc.contributor.coauthor | Ebik, Berat | |
dc.contributor.coauthor | Higuera-de la Tijera, Fatima | |
dc.contributor.coauthor | Çalışkan, Ali R. | |
dc.contributor.coauthor | Peralta, Mirta | |
dc.contributor.coauthor | Gerussi, Alessio | |
dc.contributor.coauthor | Massoumi, Hatef | |
dc.contributor.coauthor | Catana, Andreea M. | |
dc.contributor.coauthor | Purnak, Tuğrul | |
dc.contributor.coauthor | Rigamonti, Cristina | |
dc.contributor.coauthor | Aldana, Andres J. G. | |
dc.contributor.coauthor | Khakoo, Nidah | |
dc.contributor.coauthor | Nazal, Leyla | |
dc.contributor.coauthor | Frager, Shalom | |
dc.contributor.coauthor | Demir, Nurhan | |
dc.contributor.coauthor | Irak, Kader | |
dc.contributor.coauthor | Melekoğlu-Ellik, Zeynep | |
dc.contributor.coauthor | Kaçmaz, Hüseyin | |
dc.contributor.coauthor | Balaban, Yasemin | |
dc.contributor.coauthor | Atay, Kadri | |
dc.contributor.coauthor | Eren, Fatih | |
dc.contributor.coauthor | Alvares-da-Silva, Mario R. | |
dc.contributor.coauthor | Cristoferi, Laura | |
dc.contributor.coauthor | Urzua, Alvaro | |
dc.contributor.coauthor | Eskazan, Tugce | |
dc.contributor.coauthor | Magro, Bianca | |
dc.contributor.coauthor | Snijders, Romee | |
dc.contributor.coauthor | Barutçu, Sezgin | |
dc.contributor.coauthor | Lytvyak, Ellina | |
dc.contributor.coauthor | Zazueta, Godolfino M. | |
dc.contributor.coauthor | Demirezer-Bolat, Aylin | |
dc.contributor.coauthor | Aydın, Mesut | |
dc.contributor.coauthor | Heurgue-Berlot, Alexandra | |
dc.contributor.coauthor | De Martin, Eleonora | |
dc.contributor.coauthor | Ekin, Nazım | |
dc.contributor.coauthor | Yıldırım, Sumeyra | |
dc.contributor.coauthor | Yavuz, Ahmet | |
dc.contributor.coauthor | Bıyık, Murat | |
dc.contributor.coauthor | Narro, Graciela C. | |
dc.contributor.coauthor | Kıyıcı, Murat | |
dc.contributor.coauthor | Kahramanoğlu-Aksoy, Evrim | |
dc.contributor.coauthor | Vincent, Maria | |
dc.contributor.coauthor | Carr, Rotonya M. | |
dc.contributor.coauthor | Günsar, Fulya | |
dc.contributor.coauthor | Reyes, Eira C. | |
dc.contributor.coauthor | Harputluoğlu, Murat | |
dc.contributor.coauthor | Aloman, Costica | |
dc.contributor.coauthor | Gatselis, Nikolaos K. | |
dc.contributor.coauthor | Üstündağ, Yücel | |
dc.contributor.coauthor | Brahm, Javier | |
dc.contributor.coauthor | Vargas, Nataly C. E. | |
dc.contributor.coauthor | Güzelbulut, Fatih | |
dc.contributor.coauthor | Garcia, Sandro R. | |
dc.contributor.coauthor | Aguirre, Jonathan | |
dc.contributor.coauthor | Anders, Margarita | |
dc.contributor.coauthor | Ratusnu, Natalia | |
dc.contributor.coauthor | Hatemi, İbrahim | |
dc.contributor.coauthor | Mendizabal, Manuel | |
dc.contributor.coauthor | Floreani, Annarosa | |
dc.contributor.coauthor | Fagiuoli, Stefano | |
dc.contributor.coauthor | Silva, Marcelo | |
dc.contributor.coauthor | İdilman, Ramazan | |
dc.contributor.coauthor | Satapathy, Sanjaya K. | |
dc.contributor.coauthor | Silveira, Marina | |
dc.contributor.coauthor | Drenth, Joost P. H. | |
dc.contributor.coauthor | Dalekos, George N. | |
dc.contributor.coauthor | Assis, David N. | |
dc.contributor.coauthor | Bjornsson, Einar | |
dc.contributor.coauthor | Boyer, James L. | |
dc.contributor.coauthor | Yoshida, Eric M. | |
dc.contributor.coauthor | Invernizzi, Pietro | |
dc.contributor.coauthor | Levy, Cynthia | |
dc.contributor.coauthor | Montano-Loza, Aldo J. | |
dc.contributor.coauthor | Schiano, Thomas D. | |
dc.contributor.coauthor | Ridruejo, Ezequiel | |
dc.contributor.coauthor | Wahlin, Staffan | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Akyıldız, Murat | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T13:45:58Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Background: we investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: we included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 3 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | Italian Ministry of University and Research (MIUR) Department of Excellence | |
dc.description.sponsorship | Project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic) | |
dc.description.version | Publisher version | |
dc.description.volume | 42 | |
dc.identifier.doi | 10.1111/liv.15121 | |
dc.identifier.eissn | 1478-3231 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR03381 | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.quartile | N/A | |
dc.identifier.scopus | 2-s2.0-85121047570 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/3667 | |
dc.identifier.wos | 729531700001 | |
dc.keywords | Autoimmunity | |
dc.keywords | Azathioprine | |
dc.keywords | Budesonide | |
dc.keywords | Liver transplantation | |
dc.keywords | Mercaptopurine | |
dc.keywords | SARS-CoV-2 | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.grantno | NA | |
dc.relation.ispartof | Liver International | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10168 | |
dc.subject | Gastroenterology and hepatology | |
dc.title | Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Akyıldız, Murat | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
Files
Original bundle
1 - 1 of 1